On May 12, 2020, the EU innovative drugs initiative announced the list of covid-19 emergency projects with a total amount of 72million euros, and Austria JLP health, the parent company of anku Biotechnology (Suzhou) Co., Ltd., was successfully selected.
The EU innovative drugs initiative was jointly established by the European Union and the European Federation of pharmaceutical industries and associations. It aims to promote the academic and industrial circles in the EU pharmaceutical field, including universities, research centers, large pharmaceutical enterprises, small and medium-sized enterprises, patient organizations and pharmaceutical regulators, to participate in the development and Research of innovative drugs, The total budget for 2014-2020 is 3.3 billion euros.
In order to cope with the COVID-19 sweeping the world and integrate the first-class R & D resources of universities, research institutes, enterprises and public institutions within the EU, the committee selected 8 projects with development strength and application prospects from 144 application projects for funding through strict expert evaluation, including 5 rapid diagnosis projects and 3 therapeutic drug projects, As the only new drug development project (MAD cov 2, modern approvals for developing antivirals against SARS CoV 2), JLP health has fully proved the company's technical strength in new drug development.
Anku Biotechnology (Suzhou) Co., Ltd., located in Baimajian life and health town in Suzhou New Area, is jointly invested and constructed by JLP health of Austria, Jiangsu Industrial Technology Research Institute and Suzhou Hi Tech Co., Ltd. It introduces the world-class amino acid resolution drug target screening technology into Suzhou, China, establishes an antiviral drug screening platform in Suzhou, and jointly develops new antiviral targets and new drugs through close cooperation with European scientists, Fight against high-risk viruses and epidemics that endanger life and benefit human health.
Professor Josef penninger, the main applicant of this project, the founder of JLP health and the chairman of anku biology, said that it is of great significance to be successfully selected into the EU innovative drug promotion program because the competitors are strong, most of them come from famous research institutions and large medical enterprises in Europe, and the success rate of application and selection is only 5%; Among all the selected projects, only the mad-cov-2 project of JLP health belongs to the real innovative project of new drug development.
According to the company's development strategy, JLP health will gradually transfer virus target screening technology and related European technology platforms to Suzhou. During the technology transfer period, the preliminary experiment of virus research was carried out in European laboratories. Once a new anti-virus effective target was found, the natural compound drugs would be screened on the experimental platform of Suzhou anku. Therefore, the inclusion of JLP health in the EU innovative drug promotion program will also substantially promote the progress of Ankou biology in the development of antiviral drugs.
